Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned an average rating of “Buy” from the fifteen brokerages that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $25.57.

Several brokerages recently commented on EXEL. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Cann restated a “hold” rating on shares of Exelixis in a research report on Thursday, July 20th. Stifel Nicolaus restated a “hold” rating and set a $26.00 target price on shares of Exelixis in a research report on Thursday. Piper Jaffray Companies restated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research report on Thursday. Finally, Deutsche Bank AG cut shares of Exelixis from a “buy” rating to a “hold” rating and lifted their target price for the stock from $26.00 to $29.00 in a research report on Thursday.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/06/exelixis-inc-exel-given-average-rating-of-buy-by-brokerages.html.

Shares of Exelixis (EXEL) traded up 3.70% during mid-day trading on Tuesday, reaching $26.66. 2,758,945 shares of the company traded hands. The company has a market capitalization of $7.84 billion, a P/E ratio of 111.08 and a beta of 1.89. The stock’s 50-day moving average is $24.89 and its 200-day moving average is $21.88. Exelixis has a 52 week low of $9.00 and a 52 week high of $28.45.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $85.27 million. During the same quarter last year, the business earned ($0.15) earnings per share. The business’s revenue for the quarter was up 173.1% compared to the same quarter last year. On average, equities analysts predict that Exelixis will post $0.25 EPS for the current fiscal year.

In other news, insider Patrick J. Haley sold 5,000 shares of Exelixis stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total transaction of $92,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl B. Feldbaum sold 32,988 shares of Exelixis stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $21.58, for a total transaction of $711,881.04. Following the sale, the director now owns 52,721 shares of the company’s stock, valued at $1,137,719.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 360,588 shares of company stock valued at $7,840,765. 5.10% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of EXEL. Fortaleza Asset Management Inc. purchased a new stake in shares of Exelixis during the first quarter worth approximately $106,000. First Quadrant L P CA purchased a new stake in shares of Exelixis during the second quarter worth approximately $144,000. Meeder Asset Management Inc. purchased a new stake in shares of Exelixis during the first quarter worth approximately $170,000. Atlantic Trust Group LLC purchased a new stake in shares of Exelixis during the first quarter worth approximately $216,000. Finally, Klingenstein Fields & Co. LLC purchased a new stake in shares of Exelixis during the first quarter worth approximately $217,000. Institutional investors and hedge funds own 80.75% of the company’s stock.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.